Øyvind Kongstun Arnesen
Vorstandsvorsitzender bei VITMED AS
Profil
Øyvind Kongstun Arnesen is currently the Chief Executive Officer & Director at VITMED AS, Chairman at Oslo Cancer Cluster NCE, Chairman at Hubro Therapeutics AS, Director at Curida AS, and Director at Cytovation.
AS (starting in 2022).
Previously, he served as the Chief Executive Officer at Ultimovacs ASA. He also held positions as the Medical Director & Head-Clinical Operations at Boehringer Ingelheim Norway KS from 2007 to 2012, Medical Director at Bristol-Myers Squibb Norway Ltd.
from 2004 to 2007, and Clinical Trial Manager at AstraZeneca.
AS in 1995 and 1996.
Mr. Arnesen obtained a doctorate degree from the University of Oslo.
Aktive Positionen von Øyvind Kongstun Arnesen
| Unternehmen | Position | Beginn |
|---|---|---|
Oslo Cancer Cluster NCE
 Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Vorsitzender | - |
| VITMED AS | Vorstandsvorsitzender | - |
Cytovation AS
 Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Direktor/Vorstandsmitglied | 15.09.2022 |
Curida AS
 Curida AS Pharmaceuticals: MajorHealth Technology Curida AS engages in the production of pharmaceutical products for other pharmaceutical companies, both in Norway and abroad. It manufactures and markets nasal and inhalation drug products. The company was founded in 1974 and is headquartered in Elverum, Norway. | Direktor/Vorstandsmitglied | - |
Hubro Therapeutics AS
 Hubro Therapeutics AS BiotechnologyHealth Technology Hubro Therapeutics AS develops and trades biomedical products and services. It offers a technology platform for cancer vaccines targeting stomach and colon cancer. The company was founded by Jon Amund Eriksen on November 20, 2018 and is headquartered in Oslo, Norway. | Vorsitzender | - |
Ehemalige bekannte Positionen von Øyvind Kongstun Arnesen
| Unternehmen | Position | Ende |
|---|---|---|
| ULTIMOVACS ASA | Vorstandsvorsitzender | 01.06.2020 |
| Boehringer Ingelheim Norway KS | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2012 |
| Bristol-Myers Squibb Norway Ltd. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2007 |
| AstraZeneca AS | Corporate Officer/Principal | 01.01.1996 |
Ausbildung von Øyvind Kongstun Arnesen
| University of Oslo | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ULTIMOVACS ASA | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Oslo Cancer Cluster NCE
Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Commercial Services |
| AstraZeneca AS | |
| Boehringer Ingelheim Norway KS | |
Curida AS
Curida AS Pharmaceuticals: MajorHealth Technology Curida AS engages in the production of pharmaceutical products for other pharmaceutical companies, both in Norway and abroad. It manufactures and markets nasal and inhalation drug products. The company was founded in 1974 and is headquartered in Elverum, Norway. | Health Technology |
| Bristol-Myers Squibb Norway Ltd. | |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Commercial Services |
| VITMED AS | |
Hubro Therapeutics AS
Hubro Therapeutics AS BiotechnologyHealth Technology Hubro Therapeutics AS develops and trades biomedical products and services. It offers a technology platform for cancer vaccines targeting stomach and colon cancer. The company was founded by Jon Amund Eriksen on November 20, 2018 and is headquartered in Oslo, Norway. | Health Technology |
